MarsBars Pfizer ( NYSE: PFE ), BioNTech ( NASDAQ: BNTX ), Moderna ( NASDAQ: MRNA ), and Novavax ( NASDAQ: NVAX ) on Wednesday reiterated their commitment to provide the U.S. with updated COVID-19 vaccines in time for an immunization drive in the fall.
In presentations published ahead of an FDA advisory committee meeting on Wednesday, the companies highlighted data supporting the efficacy and safety of their vaccines adjusted for new COVID Omicron variants KP.2 and JN.1.
The regulator has convened its Vaccines and Related Biological Products Advisory Committee to determine the formula for next generation of COVID-19 vaccines. In May, the FDA postponed the meeting as COVID-19 continued to evolve from the Omicron XBB.1.
5 variant that the previous set of vaccines targeted. According to the latest CDC data, KP.2 and JN.
1 accounted for ~29% and ~8% of COVID cases in the U.S. for the two-week period ending May 25, respectively, compared to ~13% and ~31% about a month ago.
Pfizer ( PFE ) and BioNTech ( BNTX ) said preparations are underway to deliver their JN.1 or KP.2- adjusted COVID vaccines immediately after FDA approval in time for the 2024/25 immunization drive.
Moderna ( MRNA ) said its vaccine supplies targeting JN.1 or KP.2 could begin as early as mid-August, subject to regulatory approval, while Novavax ( NVAX ) noted its plans to start the U.
S. deliveries of its protein-based JN.1-adjusted shot in August.
More on BioNTech, Moderna, etc. Moderna, Inc. (MRNA) Moderna Oncology.
